Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression - PubMed (original) (raw)
. 2001 Aug 15;98(4):1070-7.
doi: 10.1182/blood.v98.4.1070.
Affiliations
- PMID: 11493453
- DOI: 10.1182/blood.v98.4.1070
Free article
Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression
E M Sotomayor et al. Blood. 2001.
Free article
Abstract
Tumor antigen-specific T-cell tolerance may limit the efficacy of therapeutic cancer vaccines. Direct presentation of antigens by tumor cells incapable of providing adequate costimulation to tumor-specific T cells has been suggested as the basis for this unresponsiveness. Using parent-into-F1 bone marrow (BM) chimeras, this study unambiguously demonstrates that the induction of this tolerant state requires T-cell recognition of tumor antigen presented by BM-derived antigen-presenting cells (APCs), not tumor cells themselves. In the absence of host APC presentation, tumor-specific T cells remained functional, even in the setting of antigen expressed by B-cell lymphomas residing in secondary lymphoid tissues. The intrinsic APC capacity of tumor cells has therefore little influence over T-cell priming versus tolerance, a decision that is regulated at the level of host APCs. (Blood. 2001;98:1070-1077)
Similar articles
- Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello IM, Levitsky HI, Sotomayor EM. Cuenca A, et al. Cancer Res. 2003 Dec 15;63(24):9007-15. Cancer Res. 2003. PMID: 14695219 - In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM. Horna P, et al. Blood. 2006 Apr 1;107(7):2871-8. doi: 10.1182/blood-2005-07-3014. Epub 2005 Dec 8. Blood. 2006. PMID: 16339406 Free PMC article. - CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs.
Haabeth OAW, Fauskanger M, Manzke M, Lundin KU, Corthay A, Bogen B, Tveita AA. Haabeth OAW, et al. Cancer Res. 2018 Aug 15;78(16):4573-4585. doi: 10.1158/0008-5472.CAN-17-2426. Epub 2018 May 11. Cancer Res. 2018. PMID: 29752262 - Intrathymic and extrathymic tolerance in bone marrow chimeras.
Sprent J, Kosaka H, Gao EK, Surh CD, Webb SR. Sprent J, et al. Immunol Rev. 1993 Jun;133:151-76. doi: 10.1111/j.1600-065x.1993.tb01515.x. Immunol Rev. 1993. PMID: 8225365 Review. - Cancer-reactive memory T cells from bone marrow: Spontaneous induction and therapeutic potential (Review).
Schirrmacher V. Schirrmacher V. Int J Oncol. 2015 Dec;47(6):2005-16. doi: 10.3892/ijo.2015.3197. Epub 2015 Oct 12. Int J Oncol. 2015. PMID: 26459860 Review.
Cited by
- Cancer stem cells: advances in knowledge and implications for cancer therapy.
Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, Zhai Z, Tanzhu G, Yang J, Zhou R. Chu X, et al. Signal Transduct Target Ther. 2024 Jul 5;9(1):170. doi: 10.1038/s41392-024-01851-y. Signal Transduct Target Ther. 2024. PMID: 38965243 Free PMC article. Review. - FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis.
Régnier P, Vetillard M, Bansard A, Pierre E, Li X, Cagnard N, Gautier EL, Guermonprez P, Manoury B, Podsypanina K, Darrasse-Jèze G. Régnier P, et al. Cell Rep Med. 2023 Dec 19;4(12):101256. doi: 10.1016/j.xcrm.2023.101256. Cell Rep Med. 2023. PMID: 38118422 Free PMC article. - The role of anti-tumor immunity of focused ultrasound for the malignancies: depended on the different ablation categories.
Zhang L, Yang C, Gao Y, Chen J, Chen W. Zhang L, et al. Int J Clin Oncol. 2022 Oct;27(10):1543-1553. doi: 10.1007/s10147-022-02219-4. Epub 2022 Aug 9. Int J Clin Oncol. 2022. PMID: 35943643 Review. - Identification of neoantigens for individualized therapeutic cancer vaccines.
Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Lang F, et al. Nat Rev Drug Discov. 2022 Apr;21(4):261-282. doi: 10.1038/s41573-021-00387-y. Epub 2022 Feb 1. Nat Rev Drug Discov. 2022. PMID: 35105974 Free PMC article. Review. - AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties.
Suarez L, Wang R, Carmer S, Bednarik D, Myint H, Jones K, Oelke M. Suarez L, et al. Transfus Med Hemother. 2020 Dec;47(6):464-471. doi: 10.1159/000512788. Epub 2020 Nov 16. Transfus Med Hemother. 2020. PMID: 33442341 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous